<table>
<thead>
<tr>
<th>Abstract Title</th>
<th>Abstract Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>A New Method for Estimating the Case Detection Fraction of an Emerging Epidemic and an Application to COVID-19</td>
<td>Theresa Ryckman</td>
</tr>
<tr>
<td>A Rule for Infectious Disease Modelers to Evaluate the Accuracy of Using Raw Case Counts to Evaluate Disease Control Effectiveness in the Presence of Population Dynamics</td>
<td>Peng Dai, PhD Candidate</td>
</tr>
<tr>
<td>Accounting for Household Transmission Dynamics in Realistic Epidemic Models</td>
<td>Fernando Alarid-Escudero, PhD</td>
</tr>
<tr>
<td>Agent-Based Simulation Study of Reopening Scenarios for Covid-19 in a Large Urban Area</td>
<td>Serin Lee</td>
</tr>
<tr>
<td>An Interactive Online Tool to Assess the Cost-Effectiveness of Different Hepatitis C Testing Pathways to Inform Hepatitis C Elimination</td>
<td>Madeline Adee, MPH</td>
</tr>
<tr>
<td>Assessing Interventions That Prevent Multiple Infectious Diseases: Simple Methods for Multi-Disease Modeling</td>
<td>Anneke Claypool, MS</td>
</tr>
<tr>
<td>Assessing the Impact of Targeted PrEP Policies Among Men Who Have Sex with Men (MSM) in Los Angeles County</td>
<td>Anthony Nguyen</td>
</tr>
<tr>
<td>Attributing Benefits of HIV Intervention Portfolios to Prevention and Treatment: An Application in Six U.S. Cities</td>
<td>Emanuel Krebs, M.A.</td>
</tr>
<tr>
<td>Can Hepatitis C Treatment with Direct-Acting Antivirals be Cost Saving? a Global Modeling Study of 158 Countries</td>
<td>Madeline Adee, MPH</td>
</tr>
<tr>
<td>Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Geospatial Cost-Effectiveness Modeling Study</td>
<td>Theresa Ryckman</td>
</tr>
<tr>
<td>Cost-Effectiveness of HIV Engagement in Care in High-Income Countries: A Systematic Review</td>
<td>Margo Wheatley, MS</td>
</tr>
<tr>
<td>Cost-Effectiveness of Interventions to Improve HIV Pre-Exposure Prophylaxis Uptake, Retention, and Adherence in Atlanta, Georgia</td>
<td>Gregory Knowlton, BA</td>
</tr>
<tr>
<td>Cost-Effectiveness of Pediatric ART Policy Options in the Presence of HIV Pretreatment NNRTI Drug Resistance in Kenya</td>
<td>Mutita Siriruchatanon, MS</td>
</tr>
<tr>
<td>Cost-Effectiveness of In-Development and Hypothetical Pneumococcal Conjugate Vaccines in Adults Aged ≥65 Years: An Exploratory Analysis</td>
<td>Kenneth J. Smith, MD, MS</td>
</tr>
<tr>
<td>COVID-19 Simulator: An Interactive Tool to Inform COVID-19 Intervention Policy Decisions in the United States</td>
<td>Jagpreet Chhatwal, PhD</td>
</tr>
<tr>
<td>Development of a Disease History Model for Lyme Disease: A Microsimulation Model Assessing Health Burden in Ontario, Canada</td>
<td>Stephen Mac</td>
</tr>
<tr>
<td>Effectiveness of Face Masks in Reducing the Spread of COVID-19: A Model-Based Analysis</td>
<td>Isabelle Rao, MS</td>
</tr>
<tr>
<td>Title</td>
<td>Author</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Effects and Cost-Effectiveness of Expanding Routine Immunization Coverage in India Using Campaign-Style Delivery: A Quasi-Experimental Study and Economic Evaluation</td>
<td>Emma Clarke-Deelder, MPhil</td>
</tr>
<tr>
<td>Epidemiological Impact and Cost-Effectiveness of Universal Meningitis B Vaccination Among College Students</td>
<td>Grace Chung, MPH</td>
</tr>
<tr>
<td>Estimating the Novel Coronavirus (COVID-19) Prevalence Using a Bayesian Approach</td>
<td>Abdullah Hamadeh, PhD</td>
</tr>
<tr>
<td>Evaluating Interventions to Eliminate Hepatitis C Among People Who Inject Drugs in the United States</td>
<td>Andrew Blake</td>
</tr>
<tr>
<td>Health and Economic Benefits of Human Papillomavirus (HPV) Vaccination Campaigns in 58 Gavi-Eligible Countries</td>
<td>Allison Portnoy, ScD</td>
</tr>
<tr>
<td>Health and Economic Benefits of Human Papillomavirus (HPV) Vaccination Campaigns in 58 Gavi-Eligible Countries</td>
<td>Allison Portnoy, ScD</td>
</tr>
<tr>
<td>Herd Immunity Effects in Cost-Effectiveness Analyses Among Low- and Middle-Income Countries</td>
<td>Siyu Ma, PhD</td>
</tr>
<tr>
<td>Is Further Research on Adult Pneumococcal Vaccine Uptake Improvement Programs Worthwhile? A Value of Information Analysis</td>
<td>Angela Wateska, MPH</td>
</tr>
<tr>
<td>Modeling Birth Cohort Trends in Hepatitis C Virus Infection and Their Implications in China</td>
<td>Kyueun Lee</td>
</tr>
<tr>
<td>Modeling Individual in-Hospital Trajectories with COVID-19 Using Discretely-Integrated Condition Event (DICE) Simulation</td>
<td>J. Jaime Caro, MDCM, FACP, FRCPC</td>
</tr>
<tr>
<td>Policy Comparison of Non-Pharmaceutical Interventions and Re-Opening in Mexico City, Mexico: Using a Near-Term Validated Model to Control COVID-19 Epidemic Peaks and Rebounds</td>
<td>Fernando Alarid-Escudero, PhD</td>
</tr>
<tr>
<td>Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis</td>
<td>Xiao Zang, PhD</td>
</tr>
<tr>
<td>Spatially Adaptive Guidelines for the Treatment of Gonorrhea to Increase the Effective Lifespan of Antibiotics: A Mathematical Modeling Study</td>
<td>Reza Yaesoubi, PhD</td>
</tr>
<tr>
<td>The Cost-Effectiveness of Routine Annual Influenza Vaccination By Age and Risk Status</td>
<td>Ellen Kim DeLuca, MPH</td>
</tr>
<tr>
<td>The Effect of Interventions to Reduce COVID-19 in a Large Urban Jail</td>
<td>Giovanni S. P. Malloy</td>
</tr>
<tr>
<td>The Impact of Structural Uncertainty in HPV Modeling: A Case Study</td>
<td>Jamie Cohen, MS</td>
</tr>
</tbody>
</table>